

Press release from Emotra AB (publ)

Göteborg, September 23, 2015

The subscription period for shares in Emotra AB (publ) starts today

Today, September 23, 2015, is the first day in the subscription period for the new share issue with right of priority in Emotra AB (publ) ("Emotra"). This new share issue is also open to the general public. The subscription period ends on October 7, 2015. If fully subscribed, this new share issue will provide Emotra with a cash injection of appr. 12.3 MSEK before issue expenses. Emotra's memorandum, teaser and the subscription form can be found on Emotra's, AktieTorget's and Sedermera Fondkommission's web sites (www.emotra.se, www.aktietorget.se and www.sedermera.se). Emotra has received written subscription commitments for a total of appr. 3.1 MSEK and subscription guarantees amounting to appr. 3.1 MSEK, which in total constitute approximately 50% of the new share volume. These guaranteed subscribers will be allocated shares in the new issue if the share issue is not fully subscribed (excluding any over-allocation option) by current shareholders and the general public. However, these guaranteed subscribers are only obligated to purchase shares for their stated guarantee amounts.

Possible over-allocation option to further broaden the Company's ownership base

To enable a further widening of the Company's shareholder base, the Board intends to decide on a directed share issue (over-allocation option) to be used if the new share issue with right of priority is fully subscribed in the first step. This over-allocation option, if applied, will be carried out under the same terms and conditions as the new share issue. If the over-allocation is fully subscribed, the Company will receive a further appr. 2 MSEK.

The offering in summary

-
- The subscription period is September 23 – October 7, 2015.
 - The subscription price is 2.85 SEK per share.
 - Allocated shares must be fully paid up no later than October 7, 2015.
 - Payment:
 - With subscription rights – Allocated shares must be fully paid up no later than October 7, 2015.
 - Without subscription rights – Notification of possible share allocation will be made through the sending of an account statement, which shall also include payment instructions.
 - The final day for trading in the company's shares, including the right to receive subscription rights, was September 16, 2015, and the first day without subscription rights is September 17, 2015.
 - Right of priority: Shareholders whose Emotra shares were registered on September 18, 2015 will have right of priority in the new share issue. Each outstanding share entitles the owner to one (1) subscription right. Six (6) subscription rights allow the shareholder to subscribe to five (5) new shares. Please note that this new share issue is also open to the general public.
 - The offering comprises 4,326,300 new shares. If fully subscribed, this new share issue will provide the Company with a cash injection of 12,329,955 SEK before issue expenses. The number of shares before the new issue is 5,191,560.
 - Emotra has received written subscription commitments for a total of appr. 3.1 MSEK and subscription guarantees amounting to appr. 3.1 MSEK, which in total constitute approximately 50% of the new share volume. These guaranteed subscribers will be allocated shares in the new issue if the share issue is not fully subscribed (excluding any over-allocation option) by current shareholders and the general public. However, these guaranteed subscribers are only obligated to purchase shares for their stated guarantee amounts.
 - To further widen the Company's shareholder base, the Board also intends to decide on a directed new share issue, a so-called over-allocation option, amounting to a further maximum of 1,995,000 SEK, to be used if the new share issue with right of priority is fully subscribed in the first step.
 - The pre-money value of this new share issue is appr. 14.8 MSEK.
 - Trading in subscription rights will be carried out on AktieTorget during the period September 23 to October 5, 2015.
 - Trading in PSS (Paid Subscribed Shares) will be carried out on AktieTorget from September 23, 2015, until the share issue has been registered at Bolagsverket. We expect this registration to be completed at the end of October 2015.
 - Emotra's share is listed on AktieTorget.
-

Complete terms and instructions for this rights issue, as well as further information about subscription commitments and subscription guarantees, can be found in our published memorandum. Emotra's memorandum, teaser and the subscription form can be found on Emotra's, AktieTorget's and Sedermera Fondkommission's web sites (www.emotra.se, www.aktietorget.se and www.sedermera.se).

A word from Claes Holmberg, Emotra's CEO

"Emotra has, in my opinion, a fantastic method for discovering depressed patients at risk of attempting suicide. We are in a commercialisation phase, in which gaining market acceptance is imperative for achieving increased sales. At present, our main focus is the completion of an ongoing multi-centre study. The results of this study will help us establish international scientific consensus about the method's safety, effectiveness, reliability and reproducibility. This consensus will facilitate a market launch of the product in Europe. At present, 16 of the 18 clinics have received ethics committee approval, which is a requirement before any clinic is allowed to start work on the trial. At present, more than 780 patients have been tested in the study and the Board estimates that the involved clinics will have tested approximately 1,800 patients by the end of this calendar year. All of these patients will be followed regarding suicide and suicide attempts for twelve months after their respective tests have been completed. To be able to complete our clinical multi-centre study, we are now carrying out a new share issue. The proceeds from this share issue will also be used to finance the Company's working capital, development of hardware and software, and preparatory market activities."

Information meetings

In connection with our new share issue, Emotra will take part in information meetings to present the company's operations and future plans. Attending these informational sessions are free of charge, and we will be serving a light snack. For registration to attend or for further information about the sessions, please contact Sedermera Fondkommission, by telephone: +46 431 47 17 00 or by e-mail to anmalan@sedermera.se.

- Göteborg, Sweden – September 23, 2015, at 6 pm. Radisson Blu Hotel, 59-65, Södra Hamngatan.
- Falköping, Sweden – September 24, 2015 at 1 pm. Pingstkyrkan, 46, Odengatan.

Financial Advisor

Emotra's Financial Advisor in connection with this new share issue is Sedermera Fondkommission.

For questions about the new share issue, please contact:

Sedermera Fondkommission

Telephone: +46 431 47 17 00

E-mail: info@sedermera.se

For further information, please contact:

Claes Holmberg, CEO

Telephone: +46 708 25 45 47

E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, www.emotra.se